A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder
The DOI matches its Crossref record.
Abstract
Objective Two parallel, 8-week double-blind studies compared olanzapine/fluoxetine combination, olanzapine, and fluoxetine in outpatients with treatment-resistant depression (TRD). Method Treatment-resistant depression was defined as a documented history of current-episode antidepressant failure plus a prospective failure on fluoxetine. Following an 8-week fluoxetine lead-in, 605 nonresponders with DSM-IV major depressive disorder were randomly assigned to olanzapine/fluoxetine combination, olanzapine, or fluoxetine. The primary outcome measure was baseline-to-endpoint mean change on the Montgomery-Asberg Depression Rating Scale (MADRS). The study was conducted from April 2002 to May 2005. Results After 8 weeks of double-blind treatment, Study 1 revealed no statistically significant therapy differences in MADRS mean change (olanzapine/fluoxetine combination: -11.0, fluoxetine: -9.4, olanzapine: -10.5). In Study 2, olanzapine/fluoxetine combination demonstrated significantly greater MADRS improvement (-14.5) than fluoxetine (-8.6, p Conclusion Patients with TRD (defined as treatment failure on 2 antidepressants) taking olanzapine/fluoxetine combination demonstrated significantly greater improvement in depressive symptoms than patients taking olanzapine or fluoxetine in 1 of 2 studies and in the pooled analysis. When considered within the context of all available evidence, olanzapine/fluoxetine combination is an efficacious therapy for patients with TRD. Clinical trials registr…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The response and remission rates seen in the antidepressant plus placebo arm were higher than those reported in the Sequenced Treatment Alternatives to Relieve Depression trial for step 3 (response rate, 16.8%; remission rate, 13.7%) and in the olanzapine-fluoxetine study (33)”
Citations
Cites
Still being checked.
Cited by
Items 201–228 of 228
Luchini, F., Cosentino, L., Pensabene, L., Mauri, M., & Lattanzi, L. (2015)
Augmentation in Treatment Resistant Depression: A stab in the dark? Outline
Southwood, K. (2014)
Lurasidone and Mood Stabilizers in Treatment-Resistant Unipolar Depression: A Case Report Study
Núñez, N. A., & Gobbi, G. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000664
Chronische und therapieresistente Depressionen (ICD-10 F3)
Schramm, E., Bauer, M., & Adli, M. (2013) · Elsevier eBooks · doi:10.1016/b978-3-437-24904-4.00011-2
The Atypical Antipsychotics as a New Generation Class of Antidepressants in Clinical Practice
Ibiyemi-Fasipe, O., & Fasipe, O. J. (2019) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_259_18
Tamayo, J. M., Ruiz, Y. P., & Ruíz, I. (2016) · Archivos de Neurociencias
P146 マイクロバブルの光散乱特性(ポスター・セッション)
土居, 七., & 岩崎, 杉. (2012) · 大会講演予講集
Current awareness in human psychopharmacology
(2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.796
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as04
&NA; (2010) · Drugs & Therapy Perspectives · doi:10.2165/11204310-000000000-00000
&NA; (2011) · Drugs & Therapy Perspectives · doi:10.2165/11207880-000000000-00000
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as04
Hierarchical and Complex Pharmacotherapy Decision-Making
Goldberg, J. F., & Stahl, S. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009181549.011
Ballon, J. S., Nunes, J. C., & Salaheldin, K. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as27
Medications for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_133
Alamer, A. S. (2025) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x251357060
Zhang, Q., Xiaowen, G., Li, W., Xiangqi, K., Haodong, W., Zheng, Y., Limin, Y., Jia, J., Mengmeng, S., Chaojuan, M., et al. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07584-8
Azim, L., Al-Ashmori, S., Butcher, C., Cipriani, A., Chew-Graham, C. A., Clare, E., Clark, E., Cole, M., Carella, S., Dixon, L., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-112677
Self-citationHsu, T., Hsu, C., Thompson, T., Carvalho, A. F., Stubbs, B., Tseng, P., Yang, F.-C., YU, C., Tu, Y., & Liang, C. (2026) · BMJ Mental Health · doi:10.1136/bmjment-2026-302656 · Cited by 1
Koppisetti, H., Rajapaksha, W., Nijhawan, H. P., Song, Y., Youssef, S. H., & Garg, S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101323
BindingDB Entry 50008859: New dual ligands for the D
BindingDB (2021) · UC San Diego · doi:10.7270/q24b34qh
한국형 우울장애 약물 치료 알고리듬 2012(IV): 소아 청소년/노인/여성
왕희령, 박원명, 박영민, 이황빈, 송후림, 정종현, 서정석, 임은성, 홍정완, 김원, et al. (2013) · 대한정신약물학회지
Metadata
- Authors
- Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S.
- Affiliations
- University of Pittsburgh (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-02-15
- Volume
- 68
- Issue
- 02
- Pages
- 224-236
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2125094332
- Cited by
- 228
- References
- 0
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 8 · 2023: 7 · 2022: 3 · 2021: 8 · 2020: 3 · 2019: 9 · 2018: 4 · 2017: 8 · 2016: 9 · 2015: 13 · 2014: 15 · 2013: 24 · 2012: 8
- FWCI
- 18.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- treatment-resistant depression, major depressive disorder, olanzapine, fluoxetine, olanzapine-fluoxetine combination, atypical antipsychotics, antidepressant non-response, remission rate, cholesterol, weight gain, hyperglycemia, adverse events, outpatients, Montgomery-Asberg Depression Rating Scale, antidepressant efficacy comparison, antipsychotic augmentation, adjunctive therapy
- MeSH terms
- Olanzapine, Adolescent, Adult, Aged, Benzodiazepines, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Middle Aged, Antipsychotic Agents, Treatment Failure, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.